Evidence mapPaperPMID 40342021Full record

ReviewInternational journal of molecular medicine2025

Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment (Review).

Muhammad Haris Sultan, Qi Zhan, Yigang Wang, Yulong Xia, Xiaoyuan Jia

Abstract readReview
In one paragraph

Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Targeting CDK2 and AURKA with Cerevisterol fromInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Muhammad Haris SultanCollege of Life Sciences and Medicine, Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci‑Tech University, Hangzhou, Zhejiang 310018, P.R. China.
Qi ZhanCollege of Life Sciences and Medicine, Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci‑Tech University, Hangzhou, Zhejiang 310018, P.R. China.
Yigang WangCollege of Life Sciences and Medicine, Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci‑Tech University, Hangzhou, Zhejiang 310018, P.R. China.
Yulong XiaCenter for Translational Medicine and Precision Medicine, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, P.R. China.
Xiaoyuan JiaCollege of Life Sciences and Medicine, Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci‑Tech University, Hangzhou, Zhejiang 310018, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a leading health issue and treatments to eradicate it, such as conventional chemotherapy, are non‑selective and come with a number of complications. The present review focuses on the relatively new area of precision oncolytic viral therapy (OVT), with genetic targeting and immune modifications that offer a new future for CRC treatment. In the present review, an overview of the selection factors that are considered optimal for an oncolytic virus, mechanisms of oncolysis and immunomodulation applied to the OVT, as well as new strategies to improve the efficacy of this method are described. Additionally, cause‑and‑effect relationships are examined for OVT efficacy, mediated by the tumor microenvironment, and directions for genetic manipulation of viral specificity are explored. The possibility of synergy between OVT and immune checkpoint inhibitors and other treatment approaches are demonstrated. Incorporating the details of the present review, biomarker‑guided combination therapies in precision OVT for individualized CRC care, significant issues and future trends in this required area of medicine are highlighted. Increasingly, OVT is leaving the experimental stage and may become routine practice; it provides a new perspective on overcoming CRC and highlights the importance of further research and clinical work.

Indexed as

Colorectal NeoplasmsGene TargetingImmunomodulationOncolytic VirotherapyOncolytic VirusesPrecision MedicineAnimalsHumansImmunotherapyTumor Microenvironmentbiomarkerscolorectal cancerimmune modulationoncolytic viral therapypersonalized treatmentprecision medicine

Identifiers

PMID40342021
PMCPMC12081034

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.